Physician profile
Weldon Richardson
NPI 1629351614
$8,256.17
in general payments reported to CMS, 2019-2025
20 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $879 · 2022: $1,534 · 2023: $2,956 · 2024: $1,638 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,542 · Travel and Lodging: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,541.74 |
| Travel and Lodging | $1,301.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $2,036.60 | 2021-2025 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $1,903.60 | 2021-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $1,787.06 | 2021-2025 | |
| Medtronic, INC. | $1,110.58 | 2021-2025 | Inceptiv, Intellis Adaptivestim, Synchromedii |
| Abbott Laboratories | $540.80 | 2021-2025 | Eterna, Proclaim |
| Lilly USA, LLC | $185.43 | 2021-2023 | Reyvow, Emgality |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.66 | 2023-2025 | Relistor |
| Nevro Corp. | $114.98 | 2021-2022 | |
| Pfizer INC. | $101.46 | 2021-2025 | |
| Vertex Pharmaceuticals Incorporated | $83.57 | 2024-2025 | |
| Averitas Pharma INC. | $67.54 | 2024-2025 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $52.15 | 2022 | |
| Collegium Pharmaceutical, INC. | $34.13 | 2021 | |
| Grt US Holding, INC. | $22.28 | 2022 | |
| Curonix LLC | $22.10 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $18.27 | 2025 | Tonmya |
| Axsome Therapeutics, INC. | $16.31 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $12.91 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.80 | 2021 | |
| Spr Therapeutics, INC | $10.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weldon Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.